Advertisement

Questions Surround Biogen's New Alzheimer's Drug05:13
Download

Play

Biogen’s Aducanumab is the first FDA approved drug that’s supposed to treat an underlying cause of Alzheimer’s Disease, but many scientists aren’t convinced that it can actually do that.

The company’s clinical trials of the drug sparked a debate over whether the drug really works, and how much patients should pay for it.

WBUR’s Angus Chen attended the Boston-based Institute for Clinical and Economic Review or ICER’s hearing on Thursday, where an independent panel of scientists considered whether the Alzheimer’s drug is beneficial to patients and worth the price.

This segment aired on July 16, 2021.

Angus Chen Twitter Reporter, CommonHealth
Angus Chen is a reporter for WBUR's CommonHealth.

More…

Deborah Becker Twitter Host/Reporter
Deborah Becker is a senior correspondent and host at WBUR. Her reporting focuses on mental health, criminal justice and education.

More…

Advertisement

Advertisement